MORGANTOWN, W.Va., July 10 /PRNewswire-USNewswire/ -- Combat-related injuries have long plagued the military in part because of multidrug-resistant bacteria. Imagine being able to spray a compound fracture with microcapsules that deliver a drug to bolster the immune system, stopping infection before it starts.
That technology might be around the corner, says Bingyun Li, Ph.D., of the
Results of the team's research involving the drug interleukin-12, a drug currently in anti-cancer clinical trials, has been published in the May issue of the journal Biomaterials. A deeper explanation of the approach, which could develop into an alternative to antibiotic therapy, is scheduled to be published in an upcoming issue of the Journal of Orthopaedic Research.
"These pioneering techniques could be important to the United States because of the wars in Iraq and Afghanistan," Li says. "The treatment of battlefield casualties is expensive, and the infection rate runs from 2 percent to 15 percent. In some cases, because the organisms have developed resistance, antibiotics don't work."
Outside the arena of warfare, millions of people could potentially be helped by the technology because infections can result whenever a biomedical device is implanted.
Li's team developed two ways to deliver interleukin-12.
The first is in microcapsules that can be injected or, potentially, delivered in a fine-mist spray directly to the site of an injury. The second is a nanocoating of interleukin-12 applied directly to stents, pacemakers, pain pumps, artificial limbs - virtually any biomed
Copyright©2009 PR Newswire.
All rights reserved